Ascendis Pharma A/S

2026. g. 6. aug. 20:06 UTC

Ascendis Pharma is trading higher after reporting significant findings from its Week 78 COACH trial, showing tripled height Z-score efficacy in children with achondroplasia.

2026. g. 4. aug. 19:36 UTC

Ascendis Pharma A/S is trading higher today, supported by positive market momentum despite recent negative economic data on U.S. core factory orders.

2026. g. 31. jūl. 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading significantly below their 20-day moving average amid broader market pressures from rising yields and inflation concerns.

2026. g. 30. jūl. 19:09 UTC

Ascendis Pharma A/S shares are lower, continuing a decline since Wednesday. The stock is near the lower end of its one-month range.

2026. g. 28. jūl. 20:01 UTC

Ascendis Pharma A/S shares are higher as the Biotechnology sub-sector advances. No specific company news was identified to explain today's price movement.

2026. g. 24. jūl. 17:46 UTC

Morgan Stanley raised its price target for Ascendis Pharma to $275, maintaining an Overweight rating as shares trade higher during Friday's session.

2026. g. 22. jūl. 18:36 UTC

Ascendis Pharma A/S shares are lower amid broader market sentiment affected by rising crude oil prices. The stock remains below its 20-day moving average.

2026. g. 21. jūl. 20:12 UTC

Ascendis Pharma A/S shares are higher in after-market trading, supported by positive sentiment from strong earnings reports from companies like 3M and General Motors.

2026. g. 20. jūl. 20:01 UTC

Ascendis Pharma A/S shares are lower today, continuing a decline from Friday's close amid notable volatility and no specific news to explain the movement.